A pharmaceutical composition is described. The composition may include a drug component and a propellant component. The drug component comprises at least one pharmaceutically acceptable salt of glycopyrrolate and at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof. At least 90 weight % of the propellant component is 1,1-difluoroethane (HFA-152a).

A method of treating intestinal gastrointestinal, or bowel disorders in a subject in need thereof includes administering to the subject a therapeutically effective amount of 15-PGDH inhibitor alone or in combination with a corticosteroid and/or TNF alpha antagonist.

A method of treating intestinal gastrointestinal, or bowel disorders in a subject in need thereof includes administering to the subject a therapeutically effective amount of 15-PGDH inhibitor alone or in combination with a corticosteroid and/or TNF alpha antagonist.

The invention is directed to natural drug compositions comprising turmeric, boswellia and ginger. Methods for the use of the inventive drug compositions in the treatment of inflammatory disorders and melanoma are within the scope of the invention.

The invention is directed to natural drug compositions comprising turmeric, boswellia and ginger. Methods for the use of the inventive drug compositions in the treatment of inflammatory disorders and melanoma are within the scope of the invention.

A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non-ionic cellulose derivative. The ophthalmic active agent is present as particles having D.sub.v90<5 μm and D.sub.v50<1 μm. The suspension may be administered to a patient for treating an ophthalmic inflammatory condition.

A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non-ionic cellulose derivative. The ophthalmic active agent is present as particles having D.sub.v90<5 μm and D.sub.v50<1 μm. The suspension may be administered to a patient for treating an ophthalmic inflammatory condition.

The present invention concerns compounds and their use in contraception. These compounds are derivatives of zafirlukast and have been found to inhibit CatSper in human sperm cells in low concentrations.

The present invention concerns compounds and their use in contraception. These compounds are derivatives of zafirlukast and have been found to inhibit CatSper in human sperm cells in low concentrations.

The present invention concerns compounds and their use in contraception. These compounds are derivatives of zafirlukast and have been found to inhibit CatSper in human sperm cells in low concentrations.